BR112018003335A2 - composições farmacêuticas compreendendo 3-(5-amino-2-metil-4-oxo-4h-quinazolina-3-il)-piperidina-2,6-diona - Google Patents

composições farmacêuticas compreendendo 3-(5-amino-2-metil-4-oxo-4h-quinazolina-3-il)-piperidina-2,6-diona

Info

Publication number
BR112018003335A2
BR112018003335A2 BR112018003335A BR112018003335A BR112018003335A2 BR 112018003335 A2 BR112018003335 A2 BR 112018003335A2 BR 112018003335 A BR112018003335 A BR 112018003335A BR 112018003335 A BR112018003335 A BR 112018003335A BR 112018003335 A2 BR112018003335 A2 BR 112018003335A2
Authority
BR
Brazil
Prior art keywords
quinazolin
dione
piperidine
oxo
amino
Prior art date
Application number
BR112018003335A
Other languages
English (en)
Inventor
walters Colin
Zou Daozhong
Ghosh Indrajit
Brumfield Jay
Bowen William
Shen Xiaoxuan
Sun Yali
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of BR112018003335A2 publication Critical patent/BR112018003335A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)

Abstract

são fornecidas neste documento composições farmacêuticas e formas de dosagem unitária únicas do composto a (3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona), ou uma mistura de enantiômeros do mesmo, um sal, pró-fármaco, solvato, hidrato, cocristal, clatrato ou um polimorfo farmaceuticamente aceitável do mesmo. também são fornecidos métodos de tratamento, administração ou prevenção do câncer usando as formas de dosagem descritas neste documento.
BR112018003335A 2015-08-27 2016-08-26 composições farmacêuticas compreendendo 3-(5-amino-2-metil-4-oxo-4h-quinazolina-3-il)-piperidina-2,6-diona BR112018003335A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562210923P 2015-08-27 2015-08-27
PCT/US2016/048905 WO2017035443A1 (en) 2015-08-27 2016-08-26 Pharmaceutical compositions comprising 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione

Publications (1)

Publication Number Publication Date
BR112018003335A2 true BR112018003335A2 (pt) 2018-09-25

Family

ID=56883865

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018003335A BR112018003335A2 (pt) 2015-08-27 2016-08-26 composições farmacêuticas compreendendo 3-(5-amino-2-metil-4-oxo-4h-quinazolina-3-il)-piperidina-2,6-diona

Country Status (17)

Country Link
US (1) US10064863B2 (pt)
EP (1) EP3340969B1 (pt)
JP (1) JP2018525422A (pt)
KR (1) KR20180039084A (pt)
CN (1) CN107921004A (pt)
AU (1) AU2016310340A1 (pt)
BR (1) BR112018003335A2 (pt)
CA (1) CA2996641A1 (pt)
CL (1) CL2018000489A1 (pt)
CO (1) CO2018002545A2 (pt)
EA (1) EA201890585A1 (pt)
EC (1) ECSP18023544A (pt)
ES (1) ES2865289T3 (pt)
HK (1) HK1252415A1 (pt)
IL (1) IL257666A (pt)
MX (1) MX2018002487A (pt)
WO (1) WO2017035443A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180023968A (ko) 2015-07-02 2018-03-07 셀진 코포레이션 혈액암 및 충실성 종양의 치료를 위한 병용 요법
EP3383398A1 (en) 2015-12-02 2018-10-10 Celgene Corporation Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
JP5388854B2 (ja) 2006-09-26 2014-01-15 セルジーン コーポレイション ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法
DK2683708T3 (da) * 2011-03-11 2018-01-29 Celgene Corp Faste former af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion og farmaceutiske sammensætninger og anvendelser deraf
AR085651A1 (es) * 2011-03-11 2013-10-16 Celgene Corp Metodos para tratar cancer usando 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona
AR099385A1 (es) * 2014-01-15 2016-07-20 Celgene Corp Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona

Also Published As

Publication number Publication date
US20170056323A1 (en) 2017-03-02
AU2016310340A1 (en) 2018-03-15
ECSP18023544A (es) 2018-04-30
CL2018000489A1 (es) 2018-08-03
MX2018002487A (es) 2018-06-15
EP3340969B1 (en) 2021-02-17
WO2017035443A1 (en) 2017-03-02
CN107921004A (zh) 2018-04-17
CO2018002545A2 (es) 2018-07-10
KR20180039084A (ko) 2018-04-17
CA2996641A1 (en) 2017-03-02
ES2865289T3 (es) 2021-10-15
HK1252415A1 (zh) 2019-05-24
IL257666A (en) 2018-04-30
EP3340969A1 (en) 2018-07-04
US10064863B2 (en) 2018-09-04
JP2018525422A (ja) 2018-09-06
EA201890585A1 (ru) 2018-11-30

Similar Documents

Publication Publication Date Title
CY1124669T1 (el) ΑΝΤΙ-ΟΙΣΤΡΟΓΟΝΙΚΑ ΦΑΡΜΑΚΑ ΤΕΤΡΑΫΔΡΟ-1Η-ΠΥΡΙΔΟ[3,4-b]INΔOΛIOY
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
PH12018500591A1 (en) Heterocyclic compounds and uses thereof
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
MX2017010477A (es) Compuestos triciclicos y usos de los mismos en medicina.
EA201650031A1 (ru) Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
EA201691302A1 (ru) Новые гетероциклические соединения
EA201991884A3 (ru) Ингибиторы g12c kras
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
TR201906325T4 (tr) Tetrazolon sübstitüeli dihidropiridinon MGAT2 inhibitörleri.
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
EA201891578A1 (ru) Композиции 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил-2,2-дифторацетамида
EA201692470A1 (ru) Фармацевтические комбинации
PH12019500568A1 (en) Dopamine-b-hydroxylase inhibitors
EA201692298A1 (ru) Производные карбоксамидов
EA201891682A1 (ru) Производное азациклического амида, способ его получения и фармацевтическое применение
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
BR112018003335A2 (pt) composições farmacêuticas compreendendo 3-(5-amino-2-metil-4-oxo-4h-quinazolina-3-il)-piperidina-2,6-diona
EA201891680A1 (ru) Производные индана в качестве модуляторов mglur7
TW201713630A (en) Substituted quinazoline compounds and methods of use thereof
MX2018015990A (es) Compuestos terapeuticos.
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]